

## Meta-analysis of coagulation disbalances in COVID-19: 41 studies and 17601 patients

1 **Polina Len<sup>1</sup>, Gaukhar Iskakova<sup>1,#</sup>, Zarina Sautbayeva<sup>1,#</sup>, Aigul**  
2 **Kussanova<sup>1,2,#</sup>, Ainur T. Tauekelova<sup>3</sup>, Madina M. Sugralimova<sup>3</sup>, Anar S.**  
3 **Dautbaeva<sup>3</sup>, Meruert M. Abdieva<sup>3</sup>, Eugene D. Ponomarev<sup>4</sup>, Alexander**  
4 **Tikhonov<sup>1</sup>, Makhabbat S. Bekbossynova<sup>3,\*</sup>, Natasha S. Barteneva<sup>1,5,6\*</sup>**

5 <sup>1</sup>School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan

6 <sup>2</sup>Core Facilities, Nazarbayev University, Nur-Sultan, Kazakhstan

7 <sup>3</sup>National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan

8 <sup>4</sup>School of Biomedical Sciences, Chinese University of Hong Kong, Shatin. Hong Kong

9 <sup>5</sup>National Laboratory Astana, Nur-Sultan, Kazakhstan

10 <sup>6</sup>Brigham and Women's Hospital, Harvard Medical School, Boston, USA

11 <sup>#</sup>These authors made an equal contribution in the study

12 <sup>\*</sup>Joint senior authors

13

14 Keywords: COVID-19; coagulopathy; thrombosis; D-dimers; platelets; fibrinogen; immature

15 reticulated platelets; prothrombin time

16

17 **Abstract**

18 **Introduction.** Coagulation parameters are important determinants for COVID-19 infection.

19 We conducted meta-analysis to assess the early hemostatic parameters in retrospective  
20 studies in association with severity of infection.

21 **Methods.** Ovid, PubMed, Web of Sciences, and Google Scholar were searched for research  
22 articles that addressed clinical characteristics of COVID-19 patients and disease severity.  
23 Results were filtered using exclusion and inclusion criteria and then pooled into a meta-  
24 analysis to estimate the standardized mean difference with 95% CI for each of five  
25 coagulation parameters (D-dimers, fibrinogen, prothrombin time, platelets count, activated  
26 partial thromboplastin time). Two authors independently extracted data and assessed study  
27 quality. To explore the heterogeneity and robustness of our findings, sensitivity and  
28 subgroup analyses were conducted. Publication bias was assessed with contour-enhanced  
29 funnel plots and Egger test by linear regression.

30 **Results.** Overall, 41 original studies (17601 patients) on SARS-CoV2 were included. For the  
31 two groups of patients, stratified by severity, we identified that D-dimers, fibrinogen,  
32 activated partial thromboplastin time, and prothrombin time were significantly higher in the  
33 severe group (SMD 0.6985 with 95%CI [0.5155; 0.8815]); SMD 0.661 with 95%CI [0.3387;  
34 0.9833]; SMD 0.2683 with 95%CI [0.1357; 0.4009]; SMD 0.284 with 95%CI [0.1472;  
35 0.4208]). In contrast, PLT was significantly lower in patients with more severe cases of  
36 COVID-19 (SMD -0.1684 with 95%CI [-0.2826; -0.0542]). Neither the analysis by the leave-  
37 one-out method nor the influence diagnostic have identified studies that solely cause  
38 significant change in the effect size estimates. Subgroup analysis showed no significant  
39 difference between articles originated from different countries but revealed that severity  
40 assessment criteria might have influence over estimated effect sizes for platelets and D-

41 dimers. Contour-enhanced funnel plots and the Egger test for D-dimers and fibrinogen  
42 revealed significant asymmetry that might be a sign of publication bias.

43 **Conclusions.** The standard coagulation laboratory parameters with exception of platelets  
44 counts are significantly elevated in patients with severe COVID-19. However, fibrinolysis  
45 shutdown requires evaluation outside conventional coagulation tests and analysis of  
46 additional specific markers related to clotting formation and PLT characteristics. We  
47 hypothesize that a proportion and parameters of immature reticulated platelets may serve as  
48 additional biomarkers for prediction of adverse events.

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

## 67 **1 Introduction**

68 In less than two years of the outbreak, the COVID-19 pandemic took almost five million  
69 lives (John Hopkins, 2021). SARS-CoV-2 is the seventh member of the large coronavirus  
70 family capable of inducing human disease (Carsana et al., 2020). Viral respiratory infections,  
71 including severe respiratory acute syndrome coronavirus (SARS-CoV), Middle East  
72 respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 may induce coagulopathy  
73 and lead to intravascular thrombi and deposition of fibrinogen (Hwang et al., 2005; Yang et  
74 al., 2005; Goeijenbier et al., 2012; WHO MERS guidelines, 2013; Giannis et al., 2020).

75 The coagulation system is activated and dysregulated during COVID-19 infection; however,  
76 characteristics of COVID-19 associated coagulopathy are different from coagulation  
77 disorders (Iba et al., 2020). Evidence of abnormal COVID-19-associated coagulation  
78 parameters appeared already in early publications from Wuhan (Chen et al., 2020; Wang et  
79 al., 2020; Zhou et al., 2020) and was supported by further publications worldwide (rev. Levi  
80 et al., 2020; Iba et al., 2020). The reported hemostatic abnormalities with COVID-19  
81 infection include increased D-dimers levels (Lippi et al., 2020; Demelo-Rodriguez et al.,  
82 2020), fibrinogen levels (Ranucci et al., 2020; Panigada et al., 2020), changes in the  
83 quantities and levels of activation of platelets (Yang et al., 2020; Lippi et al., 2020; Hottz et  
84 al., 2020; Althaus et al., 2021), elevated von Willebrand factor (Goshua et al., 2020;  
85 Doevelaar et al., 2021, rev. by Becker et al., 2021) and other coagulation parameters.  
86 Persistently elevated thrombocytic events, even with initiation of prophylactic anti-  
87 coagulation, suggest the presence of hypofibrinolysis in addition to detected  
88 hypercoagulability in COVID-19 (Creel-Bulos et al., 2021; Bachler et al., 2021). It is also  
89 consistent with results of thromboelastography (TEG) reported by Wright et al. (2020).

90 There is a need in early detection of elevated coagulation biomarkers to optimize risk  
91 stratification of patients with COVID-19. However, due to limitations of early pandemic

92 research with small study sizes and highly heterogeneous datasets it is still debated. The aim  
93 of the current study was to evaluate the validity of stratification based on early coagulation  
94 parameters provided by different clinical studies worldwide. We also aimed to use subgroup  
95 analysis to explore whether heterogeneity in results was in part explained by differences in  
96 patient subpopulations. Finally, the coagulation parameters of our own cohort were included  
97 in a systematic meta-analysis of published studies.

## 98 **2 Materials and Methods**

99 In this study, we aimed to identify the relationship between coagulation biomarkers taken at  
100 admission and severity of COVID-19 in adult (>18) patients by estimating the effect size of  
101 five laboratory coagulation tests: D-dimers, platelets, fibrinogen, activated partial  
102 thromboplastin time, and prothrombin time.

### 103 **2.1 Search Strategy, Exclusion and Inclusion criteria**

104 To broaden our search, we included Ovid, PubMed, Web of Sciences, and Google Scholar  
105 in the study. They were thoroughly scanned using the following keywords: SARS-CoV-2,  
106 COVID-19, coagulation, severity, characteristics, features, D-dimers, platelets, fibrinogen,  
107 cohort, observational, retrospective. First, satisfying search results were exported to an Excel  
108 table and duplicates were eliminated. Second, we conducted a preliminary review of retrieved  
109 articles' abstracts. Papers that focused on pregnant women, children, or specific age groups  
110 were avoided. Similarly, works that focused on the effect of medical treatment or patients  
111 with particular commodities were not included in the meta-analysis. We also excluded studies  
112 that compared mortality among groups of COVID-19 patients. Then, each publication was  
113 checked according to the inclusion criteria: sample size, severity assessment criteria, presence  
114 of at least one coagulation marker of interest expressed as a continuous variable. To be  
115 included, a study should have had more than 15 patients and divided them according to the

116 disease severity - WHO guidelines, ICU admission, disease aggravation, or need for oxygen  
117 therapy. Next, a list of biomarkers should have included at least some of the coagulation  
118 parameters: platelets count (PLT), D-dimers (DD), fibrinogen (FIB), activated partial  
119 thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), Activated  
120 thrombin (AT), Factor VIII (FVIII), and Von Willebrand factor (vWF). Finally, the quality of  
121 selected articles was assessed with the NIH Quality Assessment Tool for Observational  
122 Cohort and Cross-Sectional studies. Questions 5, 6, 12, 13 were not applicable to selected  
123 studies due to their observational/retrospective nature; Question 8 was not applicable to  
124 studies with dichotomous exposure values, like ICU admission and need for oxygen therapy.  
125 Hence, studies with a quality score of less than five were excluded from the analysis. Search,  
126 and quality check were conducted independently by two authors. Disagreements were  
127 resolved during a joint discussion with a third author.

## 128 **2.2 Data extraction**

129 The primary goal was to retrieve from each article data about two groups of patients  
130 differing by disease severity: group size, stratification criteria, results of the laboratory tests.  
131 Apart from these, we kept a record of the country, hospital, and admission time in order to  
132 identify and exclude duplicate patients.

## 133 **2.3 Cohort from the National Research Center for Cardiac Surgery**

### 134 **2.3.1 Participants and data collection**

135 From a large cohort of 560 patients consecutively admitted from June 2020 to August 2021  
136 due to coronavirus infection to the cardiology department of the NCJSC “National Research  
137 Center for Cardiac Surgery” (NRCCS), Nur-Sultan, Kazakhstan, we selected 451 patients  
138 with a confirmed diagnosis of COVID-19, aged  $\geq 18$  years, and those with the onset of the  
139 disease  $\leq 21$  days, all of whom were hospitalized for at least 24 hours with COVID-19. All

140 demographic, clinical, laboratory data were extracted from the electronic records of the  
141 NRCSC. Laboratory tests included PLT, PT, international normalized ratio, APTT, FIB, DD.  
142 Blood samples were collected at admission by the clinical team. Clotting tests were  
143 performed according to standard methods. For coagulation tests (PT, international normalized  
144 ratio, APTT, FIB), we used AVATUBE® with sodium citrate, and it was measured on  
145 Sysmex CS-2500 (Sysmex, Japan). Blood for DD was collected in AVATUBE® with  
146 sodium citrate, and D-dimers were quantified on Cobas® 6000. PLT counts were measured  
147 on Sysmex XS-500 (Sysmex, Japan) with blood collection performed in AVATUBE® with  
148 K2 EDTA. The confirmation of SARS-CoV-2 infection was done by real-time quantitative  
149 reverse-transcription polymerase chain reaction (RT-PCR) assay on nose/throat swab or  
150 sputum samples using CFX96® Real-Time System (Bio-Rad Laboratories, Inc., USA).

### 151 **2.3.2 Clinical assessment**

152 The COVID-19 population was initially divided into four groups according to disease  
153 severity following local guidelines “Diagnosis and treatment of Covid-19 in Adults”  
154 (<http://www.rcrz.kz/index.php/ru/2017-03-12-10-51-13/klinicheskie-protokoly>) (**Suppl. File**  
155 **1**). The study protocol was approved by the medical ethics committee of the National  
156 Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan waiving the need for written  
157 informed consent due to the retrospective design.

## 158 **2.4 Data analysis**

### 159 **2.4.1 Data transformation**

160 All data analysis was performed in the RStudio 1.4.1717 with R version 4.1.0 (Integrated  
161 Development Environment for R. RStudio, PBC, USA). In the most of cases, results were  
162 reported as the first, second (median), and third quartiles, reflecting that original data was not  
163 normally distributed. The “estmeansd” package was used to convert median, interquartile  
164 range, minimum and maximum values to mean and standard deviation. The package

165 implements Box Cox transformation to normalize raw data prior to conversion. Then, Lou  
166 (2018) formulas for mean and Wan (2014) formulas for standard deviation are used. Since  
167 the criteria and number of groups differed from study to study, patients had to be regrouped  
168 into the more and less severe groups accordingly: severe/critical and mild/moderate, ICU  
169 admitted patients and outpatients/general ward patients, observed aggravation and  
170 recovery/stable, and need for oxygen therapy.

#### 171 **2.4.2 Meta-analysis**

172 The “meta” and “metafor” packages were used for the meta-analysis. Heterogeneity was  
173 assessed using the  $I^2$ , tau-squared, and prediction intervals. Following the recommendations  
174 of Veroniki (2016), Paule-Mandel (PM) tau-squared estimator and Q-Profile (QP) tau-  
175 squared confidence interval estimator were used in this meta-analysis. To account for  
176 different measurement scales and possible inaccuracy of the Graph Digitizer, the standardized  
177 mean difference (SMD), or Hedges  $g$ , based on the inverse-variance approach, was estimated.  
178 For datasets with high heterogeneity, the Knapp-Hartung adjusted random-effects model is  
179 implemented. In case of low heterogeneity, the fixed-effects model is applied.


#### 180 **2.4.3 Sensitivity and Subgroup analysis**

181 We also performed several sensitivity analyses using the “dmetar” package. First, we  
182 recalculated the effect size using the leave-one-out method. Second, basic outliers, studies  
183 whose confidence intervals do not overlap with the pooled effect confidence interval, were  
184 removed. Third, we ran the diagnostic for influential cases with Graphic Display of Study  
185 Heterogeneity (GOSH) plots and excluded them from the meta-analysis. To further explore  
186 the heterogeneity of the data, we conducted subgroup analyses: based on grouping criteria  
187 and location.

#### 188 **2.5 Publication Bias**



189 We used the counter-enhanced Funnel plots and Egger's test by linear regression to assess  
190 the possibility for publication bias in selected studies.



191

192 **Figure 1.** Flow diagram illustrating the process of data collection.

193

### 194 3 Results


#### 195 3.1 Results of the Web Search

196 The stepwise process of selection is depicted in Figure 1. Initially, there were 4056 papers  
197 that matched search parameters. After the removal of duplicates and studies that did not meet  
198 the exclusion criteria, only 195 unique studies remained. A more thorough review based on  
199 the inclusion criteria has proven 125 studies to be unfitting. In addition to 70 that were left,

200 15 studies were extracted from the references lists of previously published meta-analyses and  
201 systematic reviews. Finally, we performed a quality check and removed duplicate patients,  
202 which resulted in 40 being included into the meta-analysis. Besides original articles, we have  
203 included data from the National Research Center for Cardiac Surgery located in Nur-Sultan,  
204 Kazakhstan. This data set included data from 451 patients with acute COVID-19.

### 205 3.2 Description of Selected Studies

206 Overall, this meta-analysis comprises 17601 patients from 40 research papers and the  
207 NRCSC. Of the total, 24 studies originated from China, while the rest included data from  
208 France, Germany, Italy, Mexico, Singapore, South Korea, Turkey, UK, and the USA. Most of  
209 the articles (23) reported division of patients according to the WHO guidelines. Out of the  
210 rest, 12 articles made groups based on the ICU admission, 3 focused on disease aggravation,  
211 and 3 on the need for oxygen therapy. This information is depicted in **Figure 2** in more  
212 detail.



213

214 **Figure 2.** Diagram depicting characteristics of selected studies: (A) number of publications  
215 per country, (B) number of patients per country, (C) number of publications per severity  
216 assessment criterion. The latter (C) indicates the total number of research articles to be 42  
217 instead of 41 because one study reported two populations of patients admitted to the hospital  
218 at different periods.

### 219 **3.3 Results of Meta-analysis**

#### 220 **3.3.1 Pooled Effect Sizes**

221 We collected data for five coagulation parameters: PLT, DD, FIB, APTT, and PT. In all  
222 cases, the heterogeneity was extremely high ( $I^2 > 80\%$ ), so the Knapp-Hartung adjusted  
223 random-effects model was applied in all parts of the meta-analysis. DD, FIB, APTT, and PT  
224 were significantly higher in more severe cases (SMD 0.6985 with 95%CI [0.5155; 0.8815];  
225 SMD 0.661 with 95%CI [0.3387; 0.9833]; SMD 0.2683 with 95%CI [0.1357; 0.4009]; SMD  
226 0.284 with 95%CI [0.1472; 0.4208]). In contrast, PLT was significantly lower in patients  
227 with severe cases of COVID-19 (SMD -0.1684 with 95%CI [-0.2826; -0.0542]). Forest plots  
228 for the meta-analyses are shown in **Figures 3-4**, and results are highlighted in **Table 1**.


229

230


231

232

### A Platelets



### B D-dimer




233


234 **Figure 3.** Forest plot of association between COVID-19 severity and platelets (A), D-dimers

235 (B).


### A Fibrinogen



### B Activated partial thromboplastin time



### C Prothrombin time



236

237 **Figure 4.** Forest plots of the association between COVID-19 severity and: (A) fibrinogen,

238 (B) activated partial thromboplastin time, (C) prothrombin time.

239

**Table 1.** Summary of the effect sizes for all coagulation parameters

Parameter	Effect Size				Heterogeneity		
	Pooled SMD	95% CI	t	p value	I <sup>2</sup> (%)	tau-squared	p value
PLT	-0.1684	[-0.2826; -0.0542]	-3	0.0051	82.2	0.0743	<0.0001
DD	0.6985	[0.5155; 0.8815]	7.74	<0.0001	94.2	0.2636	<0.0001
FIB	0.661	[0.3387; 0.9833]	4.27	0.0003	90.4	0.4812	<0.0001
APTT	0.2683	[0.1357; 0.4009]	4.22	0.0004	82.8	0.0558	<0.0001
PT	0.284	[0.1472; 0.4208]	4.3	0.0003	80	0.0785	<0.0001

240


### 241 3.3.2 Sensitivity and Subgroup Analysis

242 Neither the analysis by the leave-one-out method nor the influence diagnostic has identified  
 243 studies that solely cause a significant change in the effect size estimates. Removal of several  
 244 outliers based on the pooled and individual confidence intervals allowed significant decrease  
 245 in heterogeneity, yet it did not affect the interpretation of the results. Adjusted effect sizes  
 246 and heterogeneity measurements are summarized in **Table 2**. All influence diagnostic plots,  
 247 such as Baujat and leave-one-out plots, Cook's distance, Covariance Ratio, etc., are provided  
 248 in the **Suppl. Figures 1-16** along with resulting Forest plots.

249 GOSH plots were built for all five models. K-means, DBSCAN, and Gaussian Mixture  
 250 Model were implemented as clustering methods. This diagnostic was not applied on PLT and  
 251 DD since they only have one cluster each (**Figure 5**); for FIB, APTT, and PT, on the other  
 252 hand, we constructed the plots and identified several possible influential cases. Original  
 253 GOSH plots for these parameters are given at **Suppl. Figures**. For fibrinogen, models that  
 254 include studies by Fu et al. (2020) and Wang et al. (2020) tend to show higher heterogeneity  
 255 and greater effect size (**Figure 6A-B**). For activated partial thromboplastin time, GOSH plot  
 256 demonstrated that studies by J. Zhao et al. (2021), H. Zhang et al (2020), and Yu et al. (2020)  
 257 increase model's heterogeneity and slightly pull the effect size to the left (**Figure 6C-E**).

258 GOSH plots of the prothrombin time effect size identified four studies, three of which (J.  
259 Zhao et al (2021), Cugno et al. (2021), and Zhou et al. (2021) pull effect size to the left  
260 (**Figure 6F-H**), and one (Bastug et al.) pulls effect size to the right (**Figure 6I**). We've  
261 excluded these studies and recalculated the pooled effect size for each parameter. Results are  
262 summarized in **Table 2**.


263 To explore the possible sources of heterogeneity and test the robustness of our data, we  
264 have conducted subgroup analyses based on articles' country of origin and criteria for  
265 severity stratification. Results are summarized in **Table 3**. Subgroup analysis showed no  
266 significant difference between articles originated from different countries but revealed that  
267 severity assessment criteria might have an influence on overestimated effect sizes for PLT  
268 and DD. High heterogeneity levels seem to be persistent over different subgroups. Being the  
269 only exception, values of APTT obtained from non-Chinese articles were less heterogenous -  
270 47.1% compared to 84.7% in studies originated in China.



271

272 **Figure 5.** GOSH diagnostic for influential cases in meta-analysis models (A) - PLT, (B) -

273 DD.



274

275 **Figure 6.** GOSH plots fixed for influential studies in meta-analysis models. **(A-B)** -

276 fibrinogen; **(C-E)** - APTT; **(F-I)** - prothrombin time.

277

278



279 **Table 2.** Summary results of the sensitivity analysis

Coagulation Parameter		Effect Size				Heterogeneity		
		Pooled SMD	95% CI	t	p value	I <sup>2</sup> (%)	tau-squared	Q test p-value
PLT	Original	-0.1684	[-0.2826; -0.0542]	-3	0.0051	82.2	0.0743	<0.0001
	Outliers removed	-0.1416	[-0.2419; -0.0412]	-2.9	0.0076	56.3	0.0287	0.0002
	Inf. Stud. removed	-	-	-	-	-	-	-
DD	Original	0.6985	[0.5155; 0.8815]	7.74	<0.0001	94.2	0.2636	<0.0001
	Outliers removed	0.621	[0.4860; 0.7560]	9.47	< 0.0001	70.2	0.073	< 0.0001
	Inf. Stud. removed	-	-	-	-	-	-	-
FIB	Original	0.661	[0.3387; 0.9833]	4.27	0.0003	90.4	0.4812	<0.0001
	Outliers removed	0.5889	[0.4141; 0.7638]	7.14	< 0.0001	85	0.0801	< 0.0001
	Inf. Stud. removed	0.4855	[0.3030; 0.6679]	5.57	< 0.0001	86.1	0.1175	< 0.0001
APTT	Original	0.2683	[0.1357; 0.4009]	4.22	0.0004	82.8	0.0558	<0.0001
	Outliers removed	0.348	[0.2450; 0.4518]	7.14	< 0.0001	38.6	0.0125	0.0532
	Inf. Stud. removed	0.3214	[0.2036; 0.4392]	5.73	< 0.0001	68.8	0.0326	<0.0001
PT	Original	0.284	[0.1472; 0.4208]	4.3	0.0003	80	0.0785	<0.0001
	Outliers removed	0.293	[0.2099; 0.3761]	7.44	< 0.0001	26.9	0.0064	0.1407

280

281

282

283 **Table 3.** Summary results of the subgroup analysis

		Inf. Stud. removed	0.283	[0.1336; 0.4325]	3.94	0.0008	81	0.0877	< 0.0001
		Effect Size			Heterogeneity				
Coag. Param.	Variable	Subgroups	k	SMD [95%CI]	I <sup>2</sup> (%)	tau-squared	p-subgroup		
PLT	Location								0.2123
		China	19	-0.2256 [-0.3747; -0.0764]	84.6	0.0694			
		Other	15	-0.1384 [-0.3037; 0.0270]	73.60%	0.0765			
		Criteria							0.0263
		Guidelines	19	-0.1618 [-0.3319; 0.0082]	85.10	0.0983			
		ICU	9	-0.1188 [-0.3056; 0.0680]	70.60	0.0308			
		Aggravation	3	-0.0948 [-0.8750; 0.6854]	74.60	0.0682			
	Oxygen Therapy	3	-0.6834 [-1.4303; 0.0636]	0.00	0				
DD	Location								0.3596
		China	23	0.7618 [0.5089; 1.0148]	94.70	0.3043			
		Other	14	0.5992 [0.3204; 0.8780]	91.60	0.1964			
		Criteria							0.0041
		Guidelines	22	0.6349 [0.4248; 0.8450]	92.10	0.1903			
		ICU	12	0.9257 [0.5007; 1.3506]	96.70	0.4027			
	Aggravation	3	0.2526 [-0.2458; 0.7510]	54.60	0.0182				
FIB	Location								0.0813
		China	11	0.9393 [0.3154; 1.5632]	93.50	0.8093			
		Other	11	0.4162 [0.1757; 0.6567]	74.50	0.0937			
		Criteria							0.156
		Guidelines	13	0.8539 [0.3128; 1.3949]	92.60	0.7496			
	ICU	8	0.4510 [0.1690; 0.7330]	84.30	0.0814				
	Aggravation	1	0.3031 [0.0253; 0.5809]	-	-				
APTT	Location								0.8248
		China	13	0.2768 [0.0730; 0.4806]	88.30	0.0872			
		Other	8	0.2499 [0.0661; 0.4337]	47.10	0.0169			
		Criteria							0.359
		Guidelines	16	0.2629 [0.1019; 0.4240]	84.70	0.0636			
		ICU	4	0.3500 [-0.1307; 0.8306]	70.60	0.052			
	Aggravation	1	0.0714 [-0.2051; 0.3480]	-	-				

PT	Location						0.9249
	China	16	0.2886 [ 0.1188; 0.4584]	81.80	0.0751		
	Other	8	0.2745 [-0.0244; 0.5734]	78.30	0.1016		
	Criteria						0.6332
	Guidelines	18	0.2889 [ 0.1401; 0.4377]	79.00	0.0628		
	ICU	5	0.2992 [-0.2853; 0.8836]	87.6	0.1962		
	Aggravation	1	0.1407 [-0.1360; 0.4175]	-	-		

284


### 285 3.3.3 Publication Bias

286 Contour-enhanced funnel plots for five coagulation parameters are depicted in **Figure 7**,  
 287 and the results of Egger's test are summarized in **Table 4**. Based on the linear regression  
 288 results, significant asymmetry is observed in published studies that included results for PLT,  
 289 DD (Intercept [p-value]: -1.297 [0.0336], 3.182 [0.0013]), and somewhat significant  
 290 asymmetry was indicated for FIB (1.872 [0.0493]). While it is impossible to predict whether  
 291 asymmetry is coming solely from publication bias, contour-enhanced funnel plots for DD and  
 292 FIB (**Figure 6B-C**) show that the number of papers with insignificant findings is very small  
 293 ( $p > 0.1$ ). This may advocate for the presence of some publication bias. In contrast, **Figure**  
 294 **6A** illustrates that even though the funnel plot for PLT has some asymmetry, there are plenty  
 295 of publications with insignificant SMDs, thus decreasing the possibility of publication bias.

296 To further explore the robustness of our findings, we have conducted several additional  
 297 tests. As reported by Zwetsloot (2017) and his colleagues, plotting SMD against its standard  
 298 error to assess the publication bias can result in distorted funnel plots, leading to false-  
 299 positive conclusions. Since SMD is necessary for our analysis and cannot be substituted, we  
 300 used a sample size-based precision estimate instead of the standard error  $- 1/\sqrt{n}$ . The resulting  
 301 funnel plots (**Supplemental Figure 16**) showed no significant distortion.

302 Similar corrections were made to Egger's test: since standardized mean difference and  
 303 standard error are not independent, we can expect the test to yield some false-positive results.

304 In our calculations, we used the corrected SE suggested by Pustejovsky and Rodgers (2019).  
305 Results are given in the **Supplemental Table 2**. The only model that was affected by this  
306 correction was FIB (intercept 2.142 with a p-value of 0.0526 compared to the initial 1.872  
307 and 0.0493), indicating that previously concluded asymmetry might have been a false  
308 positive. Interpretation of results for other parameters remained the same.



309  
310 **Figure 7.** Contour-enhanced funnel plots evaluating the presence of publication bias in the  
311 pool of articles that report association between COVID-19 severity and (A) platelets; (B) D-  
312 dimer; (C) fibrinogen; (D) activated partial thromboplastin time; (E) prothrombin time.

313 **Table 4.** Egger's test for publication bias

Parameter	Intercept	Confidence Interval	t	p-value
PLT	-1.297	[-2.44, -0.15]	-2.221	0.0336
DD	3.182	[ 1.39, 4.97]	3.489	0.0013
FIB	1.872	[0.12, 3.63]	2.093	0.0493
APTT	0.775	[-1.37, 2.92]	0.708	0.4874
PT	-0.436	[-2.49, 1.62]	-0.417	0.6811

314

#### 315 **4. Discussion**

316 There is a need to identify early indicators of the risk of critical patients progressing to  
317 ICU at COVID-19. Abnormal coagulation parameters, including DD and FIB levels, changes  
318 in PLT, and PT, are observed in many patients with COVID-19 infection at admission (rev.  
319 Levi et al., 2020; Iba et al., 2020). However, as discussed by different authors, these  
320 indicators provide contradictory information regarding risk stratification and prognosis (Luo  
321 et al., 2020; Tang et al., 2020; Ding et al., 2021). There are several previous meta-analysis  
322 reviews researching abnormal coagulation and the severity of COVID-2019 infection. The  
323 majority of analyzed studies were conducted at the beginning of the pandemic and examined  
324 the Chinese population of patients (before April 2020 - Xiong et al., 2020; Lippi et al., 2020;  
325 Zhang et al., 2020; Zhu et al., 2021; June 2020 -Di Minno et al., 2020). Through our meta-  
326 analysis study, it was revealed that DD and FIB levels, APTC, and prothrombin time were  
327 significantly higher in the severe group of COVID-19 patients. In contrast, PLT was  
328 significantly lower in these patients. There was no evidence of effects across different  
329 geographic subgroups, with the exception of APTT values.

330

#### 331 **4.1 Platelet changes**

332 In this meta-analysis, we systematically analyze evidence for the utility of lowered PLT  
333 levels on admission in the relationship to the severity of infection. Platelets play a crucial role  
334 in the maintenance of hemostasis, contribute to thromboinflammatory processes (van der  
335 Meijden, Heemskerk, 2019) and at different stages of viral infection, changes in platelet  
336 production or destruction may result in coagulation imbalances leading to pro-thrombotic  
337 events or in platelet dysfunction and bleeding risks (Assinger, 2014), and increased activation  
338 of platelets (Hottz et al., 2020; Zaid et al., 2020; Althaus et al., 2021). Thrombocytopenia  
339 (platelet count  $<150 \times 10^9/L$ ) seems to represent an important marker of COVID-19 severity  
340 (Qu et al., 2020; Yang et al., 2020; Lippi et al., 2020; Iba et al., 2020) and mortality outcome  
341 (Lippi et al., 2020; Yang et al., 2020). The reasons for a thrombocytopenia are multi-factorial,  
342 which may include early suppression of megakaryocytes production and damage in bone  
343 marrow and lungs, hemophagocytosis, immune destruction of platelets and other reasons.  
344 Significant thrombocytopenia in COVID-19 is less frequent than it was reported for the  
345 largest SARS-1 cohort (45%) (Lee et al., 2003). SARS-1 induced platelet depletion was  
346 related to direct infection of megakaryocytes and hematopoietic progenitors (rev. by Yang et  
347 al., 2005). However, almost half of patients presented thrombocytosis following initial  
348 thrombocytopenia during SARS epidemics in 2003 (Wong et al., 2003). Recently, a different  
349 trend in platelet changes in COVID-19 patients with immune thrombocytic purpura (ITP) was  
350 reported by Cruz-Benito et al. (2021). Secondary to SARS-CoV2 infection in ITP-patients  
351 generally develops early thrombocytosis (Cruz-Benito et al., 2020). Only a few cases of  
352 thrombocytosis (in children) were reported during SARS-CoV2 pandemics (Feld et al., 2020)  
353 as part of a multisystem inflammatory syndrome in children associated with COVID-19  
354 (MIS-C) (Yasuhara et al., 2020). It is possible that opposite PLT changes may reflect  
355 different phases of COVID-19 infection (Thachil et al., 2020) – acute and convalescent

356 phases, though the explanation has not been established yet. The reactive thrombocytosis that  
357 may occur during the convalescent phase requires time observation that would include a  
358 period preceding patient discharge. The increase of immature reticulated platelets reported  
359 recently in COVID-19 patients by different groups (Cohen et al., 2021; Welder et al., 2021)  
360 may play a role in the limiting of effectiveness of anti-platelet therapies (Guthikonda et al.,  
361 2007; Ibrahim et al., 2012; Armstrong et al., 2017). Change in platelets parameters (increased  
362 mean volume) (Lippi et al., 2021) and reactivity are suggested to be associated with a severe  
363 COVID-19 infection (Hottz et al., 2020; Yatim et al., 2021).

#### 364 **4.2 DD and FIB levels, and Thromboembolic complications**

365 Concordant with other studies, we found DD and FIB levels significantly elevated in  
366 severe COVID-19 infection, though DD levels results may suffer from some publication bias  
367 as revealed by meta-regression analysis. It may be related to the variability of DD assays used  
368 in the different studies: they are not directly comparable due to the difference in the  
369 monoclonal antibodies used for tests (Olson et al., 2013; rev. Goodwin et al., 2017). As  
370 confirmed by autopsy results, the elevated DD levels can be associated with fibrin deposits  
371 within pulmonary extravascular space and alveoli (Fox et al., 2020), but they may be  
372 nonspecific to intravascular fibrin formation (Hunt et al., 2020). High DD levels, together  
373 with elevated neutrophils, were reported to be predictive factors of pulmonary embolism in  
374 COVID-19 patients (Thoreu et al., 2021). Thromboembolic complications related to COVID-  
375 19 are responsible for a substantial mortality rate (Lodigiani et al., 2020; Kunutsor,  
376 Laukannen, 2020; Piazza et al., 2020; Grillet et al., 2020). Whereas the highest burden of  
377 thromboembolism is associated with patients in the ICU (Helms et al., 2020; Llitjos et al.,  
378 2020; Klok et al., 2020), patients in non-ICU settings also bear a significant risk of these  
379 complications, especially VTE (venous thromboembolism) (Lodigiani et al., 2020;  
380 Spyropoulos et al., 2020), as well as pulmonary embolism (Thoreau et al., 2021). Klock and

381 colleagues (2020) report that in spite of thrombosis prophylaxis, a high incidence of  
382 thrombotic complications in ICU patients is comparable with patients from other groups with  
383 DIC (disseminated intravascular coagulation). Moreover, multiple studies describe cerebral  
384 venous thrombosis (CVT) associated with COVID-19 infection (Garaci et al., 2020; Baudar  
385 et al., 2020). DD and FIB levels are elevated in COVID-19 and in thromboembolism, and  
386 therefore as single tests are unspecific and unhelpful in the differentiation of these conditions.  
387 In part, it may be explained by the involvement in abnormal coagulation at COVID-19 of  
388 different systems, including endothelial cells, complement activation, and hypofibrinolysis  
389 resulting in changes undetected by routine tests (Holter et al., 2020; Cugno et al., 2021). The  
390 dysfunction of endothelial cells with COVID-19 may contribute to excess thrombin  
391 generation and fibrinolysis shutdown, which is associated with VTE, stroke and, renal failure  
392 (Wright et al., 2020). There are different suggestions for COVID-19 risk stratification related  
393 to changes in platelets and endothelial cells, such as increased proportion of immature  
394 reticulated platelet fraction (Cohen et al., 2021; Welder et al., 2021) or CECs (circulating  
395 endothelial cells) counts in the blood representing stressed cells detached from injured  
396 vessels, reported in various inflammatory and infective diseases, and are indicative of disease  
397 severity (Blann et al., 2006). They were significantly higher in COVID-19 patients admitted  
398 to the ICU and positively correlated with the length of hospital stay (Guervilly et al., 2020).  
399 This marker is related to SARS-CoV2 directly infecting primary endothelial cells (Monteil et  
400 al., 2020). Furthermore, there is some evidence of infection in endothelial cells in severe  
401 cases of COVID-19 (Varga et al., 2020), including the presence of coronavirus particles in  
402 the cytoplasm of endothelial cells on electron microscopy (Colmenero et al., 2020). Platelets  
403 activation and endothelial cell damage in COVID-19 patients are also resulting in elevated  
404 levels of extracellular vesicles (EVs) (Capellano et al., 2021) recently associated with  
405 severity of disease (Krishnamachary et al., 2021).



### 406 **4.3 Fibrinolysis shutdown requires evaluation outside conventional coagulation** 407 **parameters**

408 Fibrinolysis shutdown is induced by severe COVID-19 infection (Tang et al., 2020;  
409 Wright et al., 2020; Collett et al., 2021) and is partly responsible for high DD and FIB levels.  
410 Some pathophysiological changes may contribute to high procoagulant conditions secondary  
411 to COVID-19 infection. Thus, low plasminogen levels (Correa et al., 2020), similar to  
412 plasminogen-related fibrinolysis observed at other viral infections such as influenza infection  
413 (Berri et al., 2013), may lead to a hypercoagulability state. A multiplexed analysis of  
414 inflammation-related gene expression (249 genes from nCounter Inflammation panel;  
415 NanoString Technologies, USA) revealed similarities between lung specimens in influenza  
416 and Covid-19 groups (Ackermann et al., 2020). Depression of fibrinolysis was reported not  
417 only in ICU patients with severe infection and clinical signs of thromboembolism (Wright et  
418 al., 2020), but also in the general unselected ICU cohort (Correa et al., 2020; Collett et al.,  
419 2020; Nougier et al., 2020). Viscoelastic testing (ROTEM, tissue-type plasminogen activator  
420 (tPA) ROTEM, TEG) and evaluation of clot formation by Clot Waveworm analysis have  
421 demonstrated a hypercoagulable state, characterized by increased clot stiffness and severely  
422 impaired fibrinolysis (Nougier et al., 2020; Collett et al., 2020; Panigada et al., 2020; Pavoni  
423 et al., 2020; Fan et al., 2021; Hulshof et al., 2021). Elevated routine coagulation parameters  
424 taken at admission may help with initial differentiation of severe and non-severe COVID-19  
425 patient groups, but they do not provide information about fibrinolysis shutdown.

426 Although our findings were consistent across different geographic groups, they were  
427 tempered by significant heterogeneity. The DD, FIB, and PLT elevation trends speak about  
428 the necessity of investigating the potential of additional specific biomarkers for stratification  
429 of COVID-19 patients at risk for fibrinolytic shutdown and associated micro-and macro-  
430 vascular events. We suggest that thorough characterization of platelets including a proportion

431 of immature reticulated platelets and their size/mean volume parameters as well as a clot  
432 formation testing requires to evaluate a risk of thromboembolic events in COVID-19 patients  
433 groups.

## 434 **5 Limitations of the study**

435 Our findings should be interpreted with some limitations. Firstly, most of the included  
436 studies were either retrospective and observational by design, thus prone to recall or  
437 misclassification bias. Second, such studies often imply recruitment by convenience  
438 sampling, in which case the representativeness of a study is questioned. The random effects  
439 model was used due to the high heterogeneity of research. In the context of this meta-  
440 analysis, several different endpoints were allowed: severity guidelines, ICU admissions,  
441 oxygen therapy requirement, and disease aggravation. In an attempt to overcome this issue,  
442 we have conducted a subgroup analysis. Third, uncontrolled variables might also pose a  
443 limitation - both the disease severity and coagulation parameters can be affected by several  
444 potential confounding variables, such as comorbidities, age, etc. Some studies have reported  
445 their results in terms of quartiles or maximum and minimum values. The necessity to convert  
446 values could potentially influence the results. Although sensitivity and subgroup analyses  
447 were conducted, some residual heterogeneity may affect the interpretation of results. Finally,  
448 the underlying mechanisms of coagulation markers at COVID-19 still need to be  
449 investigated.

## 450 **6 Conclusions**

451 Our findings support using a combination of coagulation parameters for risk stratification  
452 of patients with COVID-19 infection at the time of admission. However, additional  
453 evaluation using clotting formation methods or combination with platelet-specific biomarkers  
454 requires. This information may help physicians triage patients with thromboembolism. An

455 important consideration is an intermediate and long follow-up of COVID-19 patients. We  
456 hypothesize that increase in platelets turnover towards immature reticulated forms contribute  
457 to hypercoagulability state at COVID-19 patients and their resistance to anti-platelet therapy.  
458 Future research should take in account change in platelet parameters and platelet  
459 fragmentation leading to elevated levels of extracellular vesicles.

## 460 **7 Data availability Statement**

461 Data are available by request from co-corresponding authors.

## 462 **8 Conflict of Interest**

463 The authors declare no conflict of interest.

## 464 **9 Author Contributions**

465 P.L. - conceptualization, methodology, formal analysis, investigation, data curation, writing  
466 original draft, G.I., Z.S., A.K. – methodology, data curation, formal analysis, investigation;  
467 A.T.T., M.M.S., A.S.D., M.M.A., M.S.B. - methodology, formal analysis, investigation, data  
468 curation of NRCSC cohort, writing a draft; E.D.P., A.T.- methodology; analysis; funding,  
469 N.S.B. - conceptualisation, methodology, formal analysis, investigation, data curation,  
470 writing a draft. M.S.B. and N.S.B.- supervision. All authors read and edit a final draft.

## 471 **10 Acknowledgments**

472 We are very grateful to Sadyk Khamitov and Aliya Sailybayeva from the Research  
473 Department of National Research Center for Cardiac Surgery for their excellent  
474 organizational help. N.S.B. and A.T. were supported by FDCRGP SSH2020028, and N.S.B.  
475 by OPCR2020018 grants from Nazarbayev University.

## 476 **11 Abbreviations**

477 APTT - activated partial thromboplastin time; CI - confidence interval; DD - D-dimer; DIC –  
478 disseminated intravascular coagulation; FIB - fibrinogen; GOSH - graphical display of study  
479 heterogeneity; ICU - intensive care unit; MERS-CoV - Middle East respiratory syndrome  
480 coronavirus (MERS-CoV); NRCSC - National Research Center for Cardiac Surgery; PLT -  
481 platelets; PT - prothrombin time; ROTEM – rotation thromboelastometry; SARS-CoV -  
482 severe respiratory acute syndrome coronavirus (SARS-CoV); SMD - standardized mean  
483 difference; tPA - tissue-type plasminogen activator; VTE - venous thromboembolism; vWF  
484 - von Willebrand factor.

485

## 486 **12 References**

487 Ackermann, M., Verleden, S.E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., et al.  
488 (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N.*  
489 *Engl. J. Med.* 383, 120-128. doi: 10.1056/NEJMoa2015432

490 Aloisio, E., Chibireva, M., Serafini, L., Pasqualetti, S.S.F., Dolci, A., Panteghini, M., et al.  
491 (2020). A comprehensive appraisal of laboratory biochemistry tests as major predictors of  
492 COVID-19 severity. *Arch. Pathol. Lab. Med.* 144, 1457-1464. doi: 10.5858/arpa.2020-0389-  
493 sa

494 Althaus, K., Marini, I., Zlamal, J., Pelzl, L., Singh, A., Häberle, H., et al. (2021). Antibody-  
495 induced procoagulant platelets in severe COVID-19 infection. *Blood.* 137, 1061–1071. doi:  
496 10.1182/blood.2020008762

497 Armstrong, P.C., Hoefler, T., Knowles, R.B., Tucker, A.T., Hayman, M.A. et al. (2017)  
498 Newly formed reticulated platelets undermine pharmacokinetically short-lived antiplatelet

499 therapies. *Atherosclerosis, Thromb. Vascular Biol.* 37, 949-956.  
500 [doi.org/10.1161/ATVBAHA.116.308763](https://doi.org/10.1161/ATVBAHA.116.308763)

501 Assinger, A. (2014). Platelets and infection-an emerging role of platelets in viral infection.  
502 *Front. Immunol.* 5, 649. doi: 10.3389/fimmu.2014.00649

503 Bastug, A., Bodur, H., Erdogan, S., Gokcinar, D., Kazancioglu, S., Deniz, B., et al. (2020).  
504 Clinical and laboratory features of COVID-19: predictors of severe prognosis. *Int.*  
505 *Immunopharmacol.* 88:106950. doi: 10.1016/j.intimp.2020.106950

506 Baudar, C., Duprez, T., Kassab, A., Miller, N., Rutgers, M.P. (2020). COVID-19 as  
507 triggering co-factor for cortical cerebral venous thrombosis? *J Neuroradiol.* 2020, 30205–  
508 302144. doi: 10.1016/j.neurad.2020.06.008

509 Bauer, W., Galtung, N., Neuwinger, N., Kaufner, L., Langer, E., Somasundaram, R., et al.  
510 (2021). A matter of caution: coagulation parameters in COVID-19 do not differ from patients  
511 with ruled-out SARS-CoV-2 infection in the emergency department. *TH Open.* 5, e43-e55.  
512 doi: 10.1055/s-0040-1722612

513 Becker, R.C., Sexton, C., Smyth, S. (2021). COVID-19 and biomarkers of thrombosis: focus  
514 on von Willebrand factor and extracellular vesicles. *J. Thromb. Thrombolysis.* 1-10. doi:  
515 10.1007/s11239-021-02544-x

516 Bergantini, L., Bargagli, E., d'Alessandro, M., Refini, R., Cameli, P., Galasso, L., et al.  
517 (2021). Prognostic bioindicators in severe COVID-19 patients. *Cytokine.* 141, 155455. doi:  
518 10.1016/j.cyto.2021.155455

519 Berri, F., Rimmelzwaan, G.F., Hanss, M., Albina, E., Foucault-Grunenwald, M.L., Le, V.B.,  
520 et al. (2013). Plasminogen controls inflammation and pathogenesis of influenza virus  
521 infections via fibrinolysis. *PLoS Pathog.* 9, e1003229. doi: 10.1371/journal.ppat.1003229

- 522 Blann, A.D., Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., et al.  
523 (2005). Circulating endothelial cells. *Thromb. Haemost.* 93, 228-235. doi: 10.1160/TH04-09-  
524 0578
- 525 Cappellano, G., Raineri, D., Rolla, R., Giordano, M., Puricelli, C., Vilardo, B., et al. (2021)  
526 Circulating platelet-derived extracellular vesicles are a hallmark of SARS-Cov-2 infection.  
527 *Cells* 10, 85. 10.3390/cells10010085
- 528 Cen, Y., Chen, X., Shen, Y., Zhang, X., Lei, Y., Xu, C., et al. (2020). Risk factors for disease  
529 progression in patients with mild to moderate coronavirus disease 2019 - a multi-centre  
530 observational study. *Clin. Microbiol. Infect.* 26, 1242-1247. doi: 10.1016/j.cmi.2020.05.04
- 531 Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020). Epidemiological and  
532 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a  
533 descriptive study. *Lancet.* 395, 507-513. doi: 10.1016/S0140-6736(20)30211-7
- 534 Chen, N., Li, Y., Fan, H., Tian, A., Yuan, H., Jiang, Z., et al. (2020). Analysis of dynamic  
535 disturbance in blood coagulation function of patients with coronavirus disease 2019: a  
536 retrospective observational study. *Medicine.* 99, e22635. doi: 510  
537 10.1097/MD.00000000000022635
- 538 Chen, Q., Zheng, Z., Zhang, C., Zhang, X., Wu, H., Wang, J., et al. (2020). Clinical  
539 characteristics of 145 patients with coronavirus disease 2019 (COVID-19) in Taizhou,  
540 Zhejiang, China. *Infection.* 48, 543–551. doi: 10.1007/s15010-020-01432-5
- 541 Chen, Z., Zhang, F., Hu, W., Chen, Q., Li, C., Wu, L., et al. (2021). Laboratory markers  
542 associated with COVID-19 progression in patients with or without comorbidity: A  
543 retrospective Study. *J. Clin. Lab. Anal.* 35, e23644. doi: 10.1002/jcla.23644

- 544 Cohen, A., Harari, E., Cipok, M., Laish-Farkash, A., Bryk, G., Yahud, E. et al. (2021).  
545 Immature platelets in patients hospitalized with COVID-19. *J. Thromb. Thrombolysis* 51,  
546 608-616. doi.org/10.1007/s11239-020-02290-6
- 547 Collett, L.W., Gluck, S., Strickland, R.M., Reddi, B.J. (2021). Evaluation of coagulation  
548 status using viscoelastic testing in intensive care patients with coronavirus disease 2019  
549 (Covid-2019): an observational point prevalence cohort study. *Austr. Crit. Care.* 34, 155-159.  
550 doi: 10.1016/j.aucc.2020.07.003
- 551 Colmenero, I., Santonja, C., Alonso-Riano, M., Hernandez-Martin, A., Andina, D., Wiesner,  
552 T., et al. (2020). SARS-CoV2 endothelial infection causes COVID-19 chilblains:  
553 histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.  
554 *Br. J. Dermatol.* 183, 729-737. doi: 10.1111/bjd.19327
- 555 Correa, T.D., Cordioli, R.L., Guerra, J.C.C., da Silva, B.C., Rodrigues, R.R., de Souza, G.M.,  
556 et al. (2020). Coagulation profile of COVID-19 patients admitted to the ICU: exploratory  
557 study. *PLoS ONE.* 15, e0243604. doi: 10.1371/journal.pone.0243604
- 558 Creel-Bulos, C., Auld, S.C., Caridi-Scheible, M., Barker, N.A., Friend, S., Gaddh, M., et al.  
559 (2021). Fibrinolysis shutdown and a thrombosis in a COVID-19 ICU. *Shock.* 55, 316-320.  
560 doi: 530 10.1097/SHK.000000000000163
- 561 Cruz-Benito, B., Rivas-Pollmar, M.I., Roman, M.T.A., Trelles-Martinez, R., Martin-Salces,  
562 532 M., Lazaro-del Campo, P. et al. (2020). Paradoxical effect of SARS-CoV2 infection with  
563 immune thrombocytopenia. *Br. J. Haematol.* 192, 973-977. doi: 10.1111/bjh.17077
- 564 Cugno, M., Meroni, P. L., Gualtierotti, R., Griffini, S., Grovetti, E., Torri, A., et al. (2021).  
565 Complement activation and endothelial perturbation parallel COVID-19 severity and activity.  
566 *J. Autoimmun.* 116, 102560. doi: 10.1016/j.jaut.2020.102560

567 Demelo-Rodriguez, P., Cervilla-Munoz, E., Ordieres-Ortega, L., Parra-Virto, A., Toledano-  
568 Macias, M. et al. (2020). Influence of asymptomatic deep vein thrombosis in patients with  
569 COVID-19 pneumonia and elevated D-dimers levels. *Thrombosis Res.* 192, 23-26. doi:  
570 10.1016/j.thromres.2020.05.018

571 Di Micco, P., Russo, V., Carannante, N., Imperato, M., Cardillo, G., and Lodigiani, C.  
572 (2020). Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency  
573 department: an Italian cohort study. *J. Clin. Med.* 9, 4134. doi: 10.3390/jcm9124134

574 Di Minno, M.N.D., Calcaterra, I., Lupoli, R., Storino, A., Spedicato, G.A., Maniscalco, M. et  
575 al. (2020) Hemostatic changes in patients with COVID-19: a meta-analysis with meta-  
576 regressions. *J. Clin. Med.* 9, 2244; doi:10.3390/jcm9072244

577 Ding, R., Yang, Z., Huang, D., Wang, Y., Li, X., Zhou, X., et al. (2021). Identification of  
578 parameters in routine blood and coagulation tests related to the severity of COVID-19. *Int. J.*  
579 *Med. Sci.* 18, 1207–1215. doi: 10.7150/ijms.47494

580 Doevelaar, A. A., Bachmann, M., Hölzer, B., Seibert, F. S., Rohn, B. J., Bauer, F., et al.  
581 (2021). Von Willebrand factor multimer formation contributes to immunothrombosis in  
582 Coronavirus disease 2019. *Critical Care Med.* 49, e512-e520. doi:  
583 10.1097/CCM.0000000000004918

584 Fan, B. E., Ng, J., Chan, S.S.W., Christopher, D., Tso, A.C.E., Ling, A.M. et al. (2021).  
585 COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state  
586 demonstrated by parameters of haemostasis and clot waveform analysis. *J. Thromb.*  
587 *Thrombolysis* 51, 663-674. doi.org/10.1007/s11239-020-02318-x



- 588 Feld, L., Belfer, J., Kabra, R., Goenka, P., Rai, S., Moriarty, S., et al. (2020). A case series of  
589 the 2019 novel coronavirus (SARS-CoV-2) in 3 febrile infants in New York. *Pediatrics*.146,  
590 e20201056. doi: 10.1542/peds.2020-1056
- 591 Fox, S.E., Akmatbekov, A., Harbert, J.L., Li, G., Brown, J.Q., and Vander Heide, R.S.  
592 (2020). Pulmonary and cardiac pathology in African American patients with COVID-19: an  
593 autopsy series from New Orleans. *Lancet Respir. Med.* 8, 681–686. doi: 10.1016/S2213-  
594 2600(20)30243-5
- 595 Fu, J., Kong, J., Wang, W., Wu, M., Yao, L., Wang, Z., et al. (2020). The Clinical  
596 implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a  
597 retrospective study in Suzhou China. *Thromb. Res.* 192, 3-8. doi:  
598 10.1016/j.thromres.2020.05.006
- 599 Garaci, F., Di Giuliano, F., Picchi, E., Da Ros, V., and Floris, R. (2020). Venous cerebral  
600 thrombosis in COVID-19 patient. *J. Neurol. Sci.* 414, 116871. doi:  
601 10.1016/j.jns.2020.116871
- 602 Gerotziafas, G. T., Sergentanis, T. N., Voiriot, G., Lassel, L., Papageorgiou, C., Elabbadi, A.,  
603 et al. (2020). Derivation and validation of a predictive score for disease worsening in patients  
604 with COVID-19. *Thromb. Haemost.* 120, 1680-1690. doi: 10.1055/s-0040-1716544
- 605 Giannis, D., Ziogas, I.A., and Gianni, P. (2020). Coagulation disorders in coronavirus  
606 infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. *J. Clin.*  
607 *Viol.* 127, 104362. doi: 10.1016/j.jcv.2020.104362
- 608 Goeijenbier, M., Van Wissen, M., Van De Weg, C., Jong, E., Gerdes, V. E. A., Meijers, J. C.  
609 M., et al. (2012). Review: viral infections and mechanisms of thrombosis and bleeding. *J.*  
610 *Med. Virol.* 84, 1680-1696. doi: 10.1002/jmv.23354

- 611 Goodwin, A.J., Higgins, R.A., Moser, K.A., Smock, K.J., Chandler, V.L., Kottke-Marchant,  
612 K., et al. (2017). Issues surrounding age-adjusted D-dimer cutoffs that practicing physicians  
613 need to know when evaluating patients with suspected pulmonary embolism. *Ann. Intern.*  
614 *Med.* 166, 361–364. doi: 10.7326/M16-2030
- 615 Goshua, G., Pine, A.B., Meizlish, M.L., Chang, C.-H., Zhang, H., Bahel, P. et al (2020).  
616 Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre,  
617 cross-sectional study. *Lancet Haematol.* 7, e575–e582. doi: 10.1016/S2352 3026(20)30216-7
- 618 Grillet, F., Behr, J., Calame, P., Aubry, S., and Delabrousse, E. (2020). Acute pulmonary  
619 embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography.  
620 *Radiology.* 23, 201544. doi: 10.1148/radiol.2020201544
- 621 Guervilly, C., Burtsey, S., Sabatier, F., Cauchois, R., Lano, G., Abdili, E., et al. (2020).  
622 Circulating endothelial cells as a marker of endothelial injury in severe COVID-19. *J. Infect.*  
623 *Dis.* 222, 1789-1793. doi: 10.1093/infdis/jiaa528
- 624 Guthikonda, S., Lev, E.I., Patel, R., DeLao, T., Bergeron, A.L., Dong, J.F., et al. (2007)  
625 Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of  
626 aspirin. *J. Thromb. Haemost.* 5, 490-496. doi:10.1111/j.1538-7836.2007.02387.x
- 627 Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., et al.  
628 (2020). High risk of thrombosis in patients with severe SARS-CoV2-infection: a multicenter  
629 prospective cohort study. *Intens. Care Med.* 46, 1089-1098. doi: 10.1007/s00134- 020-06062-  
630 x
- 631 Higuera-de-la-Tijera, F., Servín-Caamaño, A., Reyes-Herrera, D., Flores-López, A., Robiou  
632 Vivero, E., Martínez-Rivera, F., et al. (2021). The Age-AST-D Dimer (AAD) regression

633 model predicts severe COVID-19 disease. *Dis. Markers*. 2021:6658270. doi:  
634 10.1155/2021/6658270

635 Holter, J.C., Pischke, S.E., de Boer, E., Lind, A., Jenum, S., Holten, A.R. et al. (2020).  
636 Systemic complement activation is associated with respiratory failure in COVID-19 patients.  
637 *Proc. Natl. Acad. USA* 117, 25018-25025

638 Hottz, E.D., Azevedo-Quintanilha, I.G., Palhinha, L., Teixeira, L., Barretto, E.A., Pao,  
639 C.R.R. et al. (2020). Platelet activation and platelet-monocyte aggregate formation trigger  
640 tissue factor expression in patients with severe COVID-19. *Blood* 136, 1330-1341.  
641 <https://doi.org/10.1182/blood.2020007252>

642 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of  
643 patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395, 10223. doi:  
644 10.1016/s0140-6736(20)30183-5

645 Hulshof, A.-M., Brueggemann, R.A.G., Mulder, M.M.G., van de Berg, T.W., Sels, J.-W.  
646 E.M., Olie, R.H. (2021) Serial EXTEM, FIBTEM, and tPA Rotational thromboelastometry  
647 observations in the Maastricht Intensive Care COVID Cohort – persistence of  
648 hypercoagulability and hypofibrinolysis despite anticoagulation. *Front. Cardiovasc. Med.* 8,  
649 654174. doi: 10.3389/fcvm.2021.654174

650 Hunt, B.J., Levi, M. (2020). The source of elevated plasma D-dimer levels in COVID-19  
651 infection. *Br. J. Haematol.* doi: 10.1111/bjh.16907

652 Hwang, D. M., Chamberlain, D. W., Poutanen, S. M., Low, D. E., Asa, S. L., and Butany, J.  
653 (2005). Pulmonary pathology of severe acute respiratory syndrome in Toronto. *Modern.*  
654 *Pathol.* 18, 1–10. doi: 10.1038/modpathol.3800247

- 655 Iba, T., Levy, J.H., Levi, M., Connors, J.M., and Thachil, J. (2020). Coagulopathy of  
656 coronavirus disease-2019. *Crit. Care. Med.* 48, 1358-1364. doi:  
657 10.1097/CCM.0000000000004458
- 658 Ibrahim, H., Nadipalli, S., DeLao, T., Guthikonda, S., Kleiman, N.S. (2012) Immature  
659 platelet fraction (IPF) determined with an automated method predicts clopidogrel  
660 hyporesponsiveness. *J. Thromb. Thrombolysis* 33, 137–42. doi:10.1007/s11239-011-0665-7.
- 661 Johns Hopkins University & Medicine (2021). The Johns Hopkins Coronavirus Resource  
662 Center (CRC). <https://coronavirus.jhu.edu/> [Accessed September 30, 2021].
- 663 Karakoyun, I., Colak, A., Turken, M., Altin, Z., Arslan, F. D., Iyilikci, V., et al. (2021).  
664 Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in  
665 hospitalized severe COVID-19 patients. *Int. Immunopharmacol.* 91, 107285. doi:  
666 10.1016/j.intimp.2020.107285
- 667 Klok, F.A., Kruip, M.J.H.A., Van der Meer, N.J.M., Arbous, M.C., Gommers, D.A.M.P.J. et  
668 al. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-  
669 19. *Thrombosis Res.* 191, 145-147. doi: 10.1016/j.thromres.2020.04.013
- 670 Krishnamachary, B., Cook, S., Kumar, A., Spikes, L., Chalise, P., Dhillon, N.K. (2021)  
671 Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate  
672 with COVID-19 disease severity. *J. Extracel. Vesicles.* 10, e12117. doi: 10.1002/jev2.12117
- 673 Kunutsor, S.K., and Laukkanen, J.A. (2020). Incidence of venous and arterial  
674 thromboembolic complications in COVID-19: a systematic review and meta-analysis.  
675 *Thrombosis Res.* 196, 27-30. doi: 10.1016/j.thromres.2020.08.022

- 676 Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G.M., et al. (2003). A major outbreak  
677 of severe acute respiratory syndrome in Hong Kong. *N. Engl. J. Med.* 348, 1986–94.  
678 <https://doi.org/10.1056/NEJMoa030685>
- 679 Levi, M., and Scully, M. (2018). How I treat disseminated intravascular coagulation. *Blood.*  
680 131, 845-854. doi: 10.1182/blood-2017-10-804096
- 681 Levi, M., Thachil, J., Iba, T., Levi, J.H. (2020). Coagulation abnormalities and thrombosis in  
682 patients with COVID-19. *Lancet Haematol.* 7, e438-440. doi: 10.1016/ S2352-  
683 3026(20)30145-9
- 684 Liao, D., Zhou, F., Luo, L., Xu, M., Wang, H., Xia, J., et al. (2020). Haematological  
685 characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a  
686 retrospective cohort study. *Lancet Haematol.* 7, e671-e678. doi: 10.1016/s2352-  
687 3026(20)30217-9
- 688 Lippi, G., Plebani, M., and Henry, B.M. (2020). Thrombocytopenia is associated with severe  
689 coronavirus disease 2019 (COVID-19) infections: a meta-analysis. *Clin. Chim. Acta* 506,  
690 145–148. doi:10.1016/j. cca.2020.03.022
- 691 Lippi, G., Henry, B.M., Favaloro, E.J. (2021). Mean platelet volume predicts severe COVID-  
692 19 illness. *Semin. Thromb. Hemost.* 47, 456-459  
693 DOI: 10.1055/s-0041-1727283
- 694 Liu, J., Liu, Z., Jiang, W., Wang, J., Zhu, M., Song, J., et al. (2020a). Clinical predictors of  
695 COVID-19 disease progression and death: analysis of 214 hospitalized patients from Wuhan,  
696 China. *Clin. Res. J.* 15, 293-309. doi: 10.1111/crj.13296

- 697 Liu, J., Zhang, S., Wu, Z., Shang, Y., Dong, X., Li, G., et al. (2020b). Clinical outcomes of  
698 COVID-19 in Wuhan, China: a large cohort study. *Ann. Intensive Care.* 10, 1-21. doi:  
699 10.1186/s13613-020-00706-3
- 700 Liu, J., Tu, C., Zhu, M., Wang, J., Yang, C., Liu, W., and Xiong, B. (2021). The Clinical  
701 course and prognostic factors of severe COVID-19 in Wuhan, China. *Medicine.* 100: e23996.  
702 doi: 10.1097/md.00000000000023996
- 703 Liu, W., Tao, Z. W., Wang, L., Yuan, M. L., Liu, K., Zhou, L., et al. (2020). Analysis of  
704 factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus  
705 disease. *Chin. Med. J.* 133, 1032–1038. doi: 10.1097/cm9.0000000000000775
- 706 Llitjos, J.-F., Leclerc, M., Chochois, C., Monsallier, J.-M., Ramakers, M., Auvray, M., et al.  
707 (2020). High incidence of venous thromboembolic events in anticoagulated severe COVID-  
708 19 patients. *J. Thromb. Haemost.* 18, 1743-1746. doi: 10.1111/jth.14869
- 709 Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T.,  
710 et al. (2020). Venous and arterial thromboembolic complications in COVID-19 patients  
711 admitted to an academic hospital in Milan, Italy. *Thromb. Res.* 191, 9–14. doi:  
712 10.1016/j.thromres.2020.04.024
- 713 Long, H., Nie, L., Xiang, X., Li, H., Zhang, X., Fu, X., et al. (2020). D-Dimer and  
714 prothrombin time are the significant indicators of severe COVID-19 and poor prognosis.  
715 *Biomed. Res. Int.* 2020, 6159720. doi: 10.1155/2020/6159720
- 716 Lopez-Castaneda, S., García-Larragoiti, N., Cano-Mendez, A., Blancas-Ayala, K., Damian-  
717 Vázquez, G., Perez-Medina, A. I., et al. (2021). Inflammatory and prothrombotic biomarkers  
718 associated with the severity of COVID-19 infection. *Clin. Appl. Thromb. Hemost.* 27, 1-9.  
719 doi: 10.1177/1076029621999099

- 720 Luo, D., Wan, X., Liu, J., and Tong, T. (2018). Optimally estimating the sample mean from  
721 the sample size, median, mid-range, and/or mid-quartile range. *Stat. Meth. Med. Res.* 27,  
722 1785–1805. doi: 10.1177/0962280216669183
- 723 Luo, L., Xu, M., Du, M., Kou, H., Liao, D., Cheng, Z., et al. (2020). Early coagulation tests  
724 predict risk stratification and prognosis of COVID-19. *Aging (Albany NY)*. 12, 15918-  
725 15937. doi: 10.18632/aging.103581
- 726 Mikami, T., Miyashita, H., Yamada, T., Harrington, M., Steinberg, D., Dunn, A., and Siau, E.  
727 (2021). Risk factors for mortality in patients with COVID-19 in New York City. *J. Gen.*  
728 *Intern. Med.* 36, 17-26. doi: 10.1007/s11606-020-05983-z
- 729 Monteil, V., Kwon, H., Prado, P., Hagelkruys, A., Wimmer, R. A., Stahl, M., et al. (2020).  
730 Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade  
731 soluble human ACE2. *Cell* 181, 905-913. doi: 10.1016/j.cell.2020.04.004
- 732 National Heart, Lung, and Blood Institute. (2019). Study quality assessment tools.  
733 <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools> [Accessed  
734 September 20<sup>th</sup>, 2021].
- 735 Noh, C. S., Kim, W. Y., and Baek, M. S. (2021). Risk factors associated with the need for  
736 oxygen therapy in patients with COVID-19. *Medicine*. 100, e25819. doi:  
737 10.1097/md.00000000000025819
- 738 Nougier, C., Benoit, R., Simon, M., Desmurs-Clavel, H., Marcotte, G., Argaud, L., et al.  
739 (2020) Hypofibrinolytic state and high thrombin generation may play a major role in SARS-  
740 Cov2 associated thrombosis. *J. Thromb. Haemost.* 18, 2215-2219. doi: 10.1111/jth.15016

- 741 Olson, J.D., Cunningham, M.T., Higgins, R.A., Eby, C.S., and Brandt, J.T. (2013). D-dimer:  
742 simple test, tough problems. *Arch. Pathol. Lab. Med.* 137, 1030-1038.  
743 doi:10.5858/arpa.2012-0296-CP
- 744 Panigada, M., Bottino, N., Tagliabue, P., Grasselli, G., Novembrino, C., Chantarangkul, V.,  
745 et al. (2020). Hypercoagulability of COVID-19 patients in intensive care unit: a report of  
746 thromboelastography and other parameters of hemostasis. *J. Thromb. Haemost.* 18, 1738-  
747 1742. doi: 10.1111/jth.14850
- 748 Pavoni, V., Ganesello, L., Pazzi, M., Stera, C., Meconi, T., Frigieri, F.C. (2020) Evaluation  
749 of coagulation function by rotation thromboelastometry in critically ill patients with severe  
750 COVID-19 pneumonia. *J. Thromb. Thrombolysis.* 50, 281-286. doi: 10.1007/s11239-020-  
751 02130-7
- 752 Piazza, G., Campia, U., Hurwitz, S., Snyder, J. E., Rizzo, S. M., Pfeferman, M. B., et al.  
753 (2020). Registry of arterial and venous thromboembolic complications in patients with  
754 COVID-19. *J. Am. Coll. Cardiol.* 76, 2060-2072. doi: 10.1016/j.jacc.2020.08.070
- 755 Pustejovsky, M.A., and Rodgers, J.E. (2019). Testing for funnel plot asymmetry of  
756 standardized mean differences. *Res. Synthesis Meth.* 10, 57-71. doi: 10.1002/jrsm.1332
- 757 Qu, R., Ling, Y., Zhang, Y.H.Z., Wei, L.Y., Chen, X., Li, X.M. et al. (2020). Platelet-to  
758 lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. *J. Med.*  
759 *Virol.* 92, 1533-1541. doi: 10.1002/jmv.25767
- 760 Ranucci, M., Ballotta, A., Di Dedda, U., Bayshnikova, E., Dei Poli, M., Resta, M., et al.  
761 (2020). The procoagulant pattern of patients with COVID-19 acute distress syndrome. *J.*  
762 *Thromb. Haemost.* 18, 1747-1751. doi: 10.1111/jth.14854



- 763 Rauch, A., Labreuche, J., Lassalle, F., Goutay, J., Caplan, M., Charbonnier, L., et al. (2020).  
764 Coagulation biomarkers are independent predictors of increased oxygen requirements in  
765 COVID-19. *J. Thromb. Haemost.* 18, 2942-2953. doi: 10.1111/jth.15067
- 766 Shang, W., Dong, J., Ren, Y., Tian, M., Li, W., Hu, J., et al. (2020). The value of clinical  
767 parameters in predicting the severity of COVID-19. *J. Med. Virol.* 92, 2188-2192. doi:  
768 10.1002/jmv.26031
- 769 Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., et al. (2020).  
770 Scientific and standardization committee communication: clinical guidance on the diagnosis,  
771 prevention and treatment of venous thromboembolism in hospitalized patients with COVID-  
772 19. *J. Thromb. Haemost.* 18, 1859–1865. doi: 10.1111/jth.14929
- 773 Suleyman, G., Fadel, R. A., Malette, K. M., Hammond, C., Abdulla, H., Entz, A., et al.  
774 (2020). Clinical characteristics and morbidity associated with coronavirus disease-2019 in a  
775 series of patients in metropolitan Detroit. *JAMA Netw. Open.* 3, e2012270. doi: 715  
776 10.1001/jamanetworkopen.2020.12270
- 777 Tang, N., Li, D., Wang, X., and Sun, Z. (2020). Abnormal coagulation parameters are  
778 associated with poor prognosis in patients with novel coronavirus pneumonia. *J. Thromb.*  
779 *Haemost.* 18, 844-847. doi: 10.1111/jth.14768
- 780 Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., et al. (2020). ISTH  
781 interim guidance on recognition and management of coagulopathy in COVID-19. *J. Thromb.*  
782 *Haemost.* 18, 1023-1026. doi: 10.1111/jth.14810
- 783 Thoreau, B., Galland, J., Delrue, M., Neuwirth, M., Stepanian, A., Chauvin, A. et al. (2021).  
784 D-Dimer levels and neutrophils count as predictive and prognostic factors of pulmonary

785 embolism in severe non-ICU COVID-19 patients. *Viruses*. 13, 758. doi: 725  
786 10.3390/v13050758

787 Van der Meijden, P.E.J., Heemskerk, J.W.M. (2019) Platelet biology and functions: new  
788 concepts and clinical perspectives. *Nature Rev. Cardiol.* 16, 166-179.  
789 <https://doi.org/10.1038/s41569-018-0110-0>

790 Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., et  
791 al. (2020). Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 395, 1417–1418.  
792 doi: 10.1016/S0140-6736(20)30937-5

793 Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., et al.  
794 (2016). Methods to estimate the between-study variance and its uncertainty in meta-analysis.  
795 *Res. Synth. Methods*. 7, 55–79. doi: 10.1002/jrsm.1164

796 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020). Clinical characteristics of  
797 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.  
798 *JAMA*. 323, 1061-1069. doi: 10.1001/jama.2020.1585

799 Wan, X., Wang, W., Liu, J., and Tong, T. (2014). Estimating the Sample Mean and Standard  
800 Deviation from the Sample Size, Median, Range and/or Interquartile range. *BMC Med. Res.*  
801 *Methodol.* 14, 1-13. doi: 10.1186/1471-2288-14-135

802 Wang, P., Sha, J., Meng, M., Wang, C., Yao, Q., Zhang, Z., et al. (2020). Risk factors for  
803 severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective  
804 study. *J. Transl. Med.* 18, 1-12. doi: 10.1186/s12967-020-02655-8

805 Wang, Y., Yao, L., Zhang, J. P., Tang, P. J., Ye, Z. J., Shen, X. H., et al. (2020). Clinical  
806 characteristics and laboratory indicator analysis of 67 COVID-19 pneumonia patients in  
807 Suzhou, China. *BMC Infect. Dis.* 20,747. doi: 10.1186/s12879-020-05468-8

- 808 Welder, D., Jeon-Slaughter, H., Ashraf, B., Choi, S.-H., Chen, W., Ibrahim, I. et al. (2021).  
809 Immature platelets as a biomarker for disease severity and mortality in COVID-19 patients.  
810 Br. J. Haem. 194, 530-536. <https://doi.org/10.1111/bjh.17656>
- 811 White, D., MacDonald, S., Edwards, T., Bridgeman, C., Hayman, M., Sharp, M., et al.  
812 (2020). Evaluation of COVID-19 coagulopathy: laboratory characterization using thrombin  
813 generation and nonconventional haemostasis assays. Int. J. Lab. Hematol. 43, 123-130. doi:  
814 10.1111/ijlh.13329
- 815 Wong, R.S., Wu, A., To, K.F., Lee, N, Lam, C.W., Wong, C.K., et al. (2003).  
816 Haematological manifestations in patients with severe acute respiratory syndrome:  
817 retrospective analysis. Br. Med. J. 326, 1358– 62.
- 818 World Health Organization. (2013). Guidelines for investigation of cases of human infection  
819 with Middle East Respiratory Syndrome Coronavirus (MERS-CoV).  
820 ([https://cdn.who.int/media/docs/default-source/documents/emergencies/health-topics---](https://cdn.who.int/media/docs/default-source/documents/emergencies/health-topics---mers/mers_cov_investigation_guideline_jul132d7b61a0-a593-4527-8246-25152b965baf.pdf?sfvrsn=3e2f6c65_1&download=true)  
821 [mers/mers\\_cov\\_investigation\\_guideline\\_jul132d7b61a0-a593-4527-8246-](https://cdn.who.int/media/docs/default-source/documents/emergencies/health-topics---mers/mers_cov_investigation_guideline_jul132d7b61a0-a593-4527-8246-25152b965baf.pdf?sfvrsn=3e2f6c65_1&download=true)  
822 [25152b965baf.pdf?sfvrsn=3e2f6c65\\_1&download=true](https://cdn.who.int/media/docs/default-source/documents/emergencies/health-topics---mers/mers_cov_investigation_guideline_jul132d7b61a0-a593-4527-8246-25152b965baf.pdf?sfvrsn=3e2f6c65_1&download=true) [Accessed September 30, 2021]
- 823 Wright, F.L., Vogler, T.O., Moore, E.E., Moore, H.B., Wohlauer, M.V., Urban, S., et al.  
824 (2020). Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19  
825 infection. J. Amer. Col. Surgeons. 231, 193-203. doi: 10.1016/j.jamcollsurg.2020.05.007
- 826 Xiong, M., Liang, X., and Wei Y.D. (2020). Changes in blood coagulation in patients with  
827 severe coronavirus disease 2019 (COVID-2019): a meta-analysis. Br. J. Haem. 189, 1050-  
828 1052. doi: 10.1111/bjh.16725
- 829 Yang, M., Ng, M. H., and Li, C. K. (2005). Thrombocytopenia in patients with severe acute  
830 respiratory syndrome. Hematology 10, 101–105. doi: 10.1080/10245330400026170

- 831 Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., et al. (2020). Thrombocytopenia and  
832 its association with mortality in patients with COVID-19. *J. Thromb. Haemost.* 18, 1469–72.  
833 doi: 10.1111/jth.14848
- 834 Yasuhara, J., Kuno, T., Takagi, H., and Sumitomo, N. (2020). Clinical characteristics of  
835 COVID 19 in children: a systematic review. *Pediatr. Pulmonol.* 55, 2565-2575. doi:  
836 10.1002/ppul.24991
- 837 Yatim, N., Boussier, J., Chocron, R., Hadjadj, J., Philippe, A., Gendron, N. (2021). Platelet  
838 activation in critically ill COVID-19 patients. *Ann. Intensive Care* 11, 113.  
839 doi.org/10.1186/s13613-021-00899-1
- 840 Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., et al. (2020).  
841 Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in  
842 Singapore. *JAMA* 323, 1488-1494. doi: 10.1001/jama.2020.3204
- 843 Yu, C., Lei, Q., Li, W., Wang, X., Li, W., and Liu, W. (2020). Epidemiological and clinical  
844 characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a  
845 single-center experience. *J. Infect. Public Health.* 13, 1202–1209. doi:  
846 10.1016/j.jiph.2020.07.002
- 847 Yue, T., Zhou, W., He, J., Wang, H., Liu, Y., Wang, B., et al. (2021). Combined clinical and  
848 imaging features better predict the critical outcomes of patients with SARS-COV-2. *Medicine*  
849 100, e25083. doi: 10.1097/md.00000000000025083
- 850 Zhang, A., Leng, Y., Zhang, Y., Wu, K., Ji, Y., Lei, S., et al. (2020). Meta-analysis of  
851 coagulation parameters associated with disease severity and poor prognosis of COVID-19.  
852 *Inter. J. Infect. Dis.* 100, 441-448. doi: 10.1016/j.ijid.2020.09.021

- 853 Zhang, H., Wang, X., Fu, Z., Luo, M., Zhang, Z., Zhang, K., et al. (2020). Potential factors  
854 for prediction of disease severity of COVID-19 patients. medRxiv [Preprint]. doi:  
855 10.1101/2020.03.20.20039818
- 856 Zhang, J., Huang, X., Ding, D., and Tao, Z. (2021). Platelet-driven coagulopathy in COVID-  
857 19 patients: in comparison to seasonal influenza cases. *Exp. Hematol. Oncol.* 10, 1-13. doi:  
858 10.1186/s40164-021-00228-z
- 859 Zhao, J., Zhu, M., Su, X., Huang, M., Yang, Y., Huang, J., et al. (2021). Clinical features and  
860 risk factors for severe-critically ill COVID-19 adult patients in Jiangsu, China. *Medicine.*  
861 100, e24332. doi: 10.1097/md.00000000000024332
- 862 Zhao, Y., Yu, C., Ni, W., Shen, H., Qiu, M., and Zhao, Y. (2021). Peripheral blood  
863 inflammatory markers in predicting prognosis in patients with COVID-19. Some differences  
864 with Influenza A. *J. Clin. Lab. Anal.* 35, e23657. doi: 10.1002/jcla.23657
- 865 Zheng, X., Chen, J., Deng, L., Fang, Z., Chen, G., Ye, D., et al. (2020). Risk factors for the  
866 COVID-19 severity and its correlation with viral shedding: a retrospective cohort study. *Int.*  
867 *J. Infect. Dis.* 93, 952-961. doi: 10.1002/jmv.26367
- 868 Zhou, C., Huang, Z., Tan, W., Li, X., Yin, W., Xiao, Y., et al. (2020). Predictive factors of  
869 severe coronavirus disease-2019 in previously healthy young adults: a single-center,  
870 retrospective study. *Respir. Res.* 21:157, 1-8. doi: 10.1186/s12931-020-01412-1
- 871 Zhu, J., Pang, J., Ji, P., Zhong, Z., Li, H., Li, B. et al. (2020) Coagulation dysfunction is  
872 associated with a severity of COVID-19. *J. Med. Virol.* 93, 962-972. doi: 10.1002/jmv.26336
- 873 Zwetsloot, P.-P., Naald, M.V.D., Sena, E.S., Howells, W.D., IntHout, J., De Groot, J.A.H. et  
874 al. (2017). Standardized means differences cause funnel plots distortion in publication bias  
875 assessments. *eLife* 6, e24260 DOI: 10.7554/eLife.24260

## 876 **Legends to the Tables**

877 **Table 1.** Summary of the effect sizes for all coagulation parameters

878 **Table 2.** Summary results of the sensitivity analysis

879 **Table 3.** Summary results of the subgroup analysis

880 **Table 4.** Egger's test for publication bias

881

882

## 883 **Legends to the Figures**

884 **Figure 1.** Flow diagram illustrating the process of data collection

885 **Figure 2.** Diagram depicting characteristics of selected studies: (A) number of publications  
886 per country; (B) number of patients per country; (C) number of publications per severity  
887 assessment criterion. The latter (C) indicates the total number of research articles to be 42  
888 instead of 41 because one study reported two populations of patients admitted to the hospital  
889 at different periods.

890 **Figure 3.** Forest plot of association between COVID-19 severity and (A) platelets; (B) D-  
891 dimers.

892 **Figure 4.** Forest plots of the association between COVID-19 severity and (A) fibrinogen; (B)  
893 activated partial thromboplastin time; (C) prothrombin time.

894 **Figure 5.** GOSH diagnostic for influential cases in meta-analysis models (A) PLT; (B) D-  
895 dimers.

896 **Figure 6.** GOSH plots fixed for influential studies in meta-analysis models (A-B) -  
897 fibrinogen; (C-E) - APTT, (F-I) - prothrombin time.

898 **Figure 7.** Contour-enhanced funnel plots evaluating the presence of publication bias in the  
899 pool of articles that report association between COVID-19 severity and (A) platelets; (B) D-  
900 dimers; (C) fibrinogen; (D) activated partial thromboplastin time; (E) prothrombin time.

901

902

### 903 **Legends to Supplementary Materials**

904 **Supplementary File 1.** Criteria for clinical severity of COVID-19 used by the National  
905 Research Center for Cardiac Surgery.

906 **Supplementary Table 1.** Results of the NIH Quality Assessment.

907 **Supplementary Table 2.** Results of the Egger's test with Pustejovsky's corrected standard  
908 error.

909 **Supplementary Figure 1.** Exploring influential cases in meta-analysis models with Baujat  
910 plots: (A) Platelets, (B) D-dimers, (C) Fibrinogen, (D) Activated partial thromboplastin time,  
911 (E) Prothrombin time.

912 **Supplementary Figure 2.** Influence diagnostic of meta-analysis model for the association of  
913 platelets count and COVID-19 severity.

914 **Supplementary Figure 3.** Influence diagnostic of meta-analysis model for the association of  
915 D-dimers concentration and COVID-19 severity.

916 **Supplementary Figure 4.** Influence diagnostic of meta-analysis model for the association of  
917 fibrinogen and COVID-19 severity.

918 **Supplementary Figure 5.** Influence diagnostic of meta-analysis model for the association of  
919 activated partial thromboplastin time and COVID-19 severity.

920 **Supplementary Figure 6.** Influence diagnostic of meta-analysis model for the association of  
921 prothrombin time and COVID-19 severity.

922 **Supplementary Figure 7.** Search for influential cases by leave-one-out method in meta-  
923 analysis models for the association of (A) platelets count, (B) D-dimers and COVID-19  
924 severity.

925 **Supplementary Figure 8.** Search for influential cases by leave-one-out method in meta-  
926 analysis models for the association of (A) fibrinogen, (B) APTT and COVID-19 severity.

927 **Supplementary Figure 9.** Search for influential cases by leave-one-out method in meta-  
928 analysis model for the association of prothrombin time and COVID-19 severity.

929 **Supplementary Figure 10.** Forest plots of association of COVID-19 severity and (A)  
930 platelets count and (B) D-dimers with outliers removed.

931 **Supplementary Figure 11.** Forest plots of association of COVID-19 severity and (A)  
932 fibrinogen, (B) activated partial thromboplastin time, and (C) prothrombin time with outliers  
933 removed.

934 **Supplementary Figure 12.** Exploring the influence of meta-analysis study composition on  
935 heterogeneity and pooled effect size: (A) fibrinogen, (B) activated partial thromboplastin  
936 time, and (C) prothrombin time.

937 **Supplementary Figure 13.** Results of three clustering methods (A) K-means, (B) DBSCAN,  
938 and (C) Gaussian Mixture on the meta-analysis model for association of fibrinogen and  
939 COVID-19 severity.



940 **Supplementary Figure 14.** Results of three clustering methods (A) K-means, (B) DBSCAN,  
941 and (C) Gaussian Mixture on the meta-analysis model for association of activated partial  
942 thromboplastin time and COVID-19 severity.

943 **Supplementary Figure 15.** Results of three clustering methods (A) K-means, (B) DBSCAN,  
944 and (C) Gaussian Mixture on the meta-analysis model for association of prothrombin time  
945 and COVID-19 severity.

946 **Supplementary Figure 16.** Exploring presence of publication bias with corrected funnel  
947 plots: SMD plotted against sample size-based precision estimate: (A) platelets, (B) D-dimers,  
948 (C) fibrinogen, (D) activated partial thromboplastin time, (E) prothrombin time.